References
- Qin Q, Wei C, Piao Y, et al. Current review of leptomeningeal amyloidosis associated with transthyretin mutations. Neurologist. 2021;26(5):189–195. doi:10.1097/NRL.0000000000000337.
- Mathieu F, Morgan E, So J, et al. Oculoleptomeningeal amyloidosis secondary to the rare transthyretin c.381T > G (p.Ile127Met) mutation. World Neurosurg. 2018;111:190–193. doi:10.1016/j.wneu.2017.12.096.
- Sousa L, Coelho T, Taipa R. CNS involvement in hereditary transthyretin amyloidosis. Neurology. 2021;97(24):1111–1119. doi:10.1212/WNL.0000000000012965.
- Suhr OB, Andersen O, Aronsson T, et al. Report of five rare or previously unknown amyloidogenic transthyretin mutations disclosed in Sweden. Amyloid. 2009;16(4):208–214. doi:10.3109/13506120903421587.
- Takahashi Y, Oguchi K, Mochizuki Y, et al. Distribution and progression of cerebral amyloid angiopathy in early-onset V30M (p.V50M) hereditary ATTR amyloidosis. Amyloid. 2023;30(1):109–118. doi:10.1080/13506129.2022.2128331.